EUVIMEDEUVIMED entdecken
Crossref

Efficacy Of The Combination Of Daclatasvir And Sofosbuvir For The Management Of Hcv Genotype 3 Patients

Sana Tahir Virk, Sadaf Yousaf, Kazim Abbas Virk, Zaid Umer, Abeer Zafar, Mahwish Ahmad

HITEC Medical and Dental Journal · 2025

DOI: 10.69884/hmdj.4.2.3963 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HITEC Medical and Dental Journal, 2025. Verfasst von Sana Tahir Virk und 5 weiteren Autor:innen. Die Arbeit nennt 17 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To determine the frequency of sustained virologic response (SVR) of Daclatasvir (DCV) plus Sofosbuvir (SOV) for the management of HCV genotype 3 infections in non-cirrhotic patients. Study Design: Prospective, observational study. Place and Duration of Study: Gastroenterology department, Shifa International Hospital Islamabad, 06 months (May to November 2019). Methodology: Total 75 diagnosed and treatment- naive patients of chronic HCV genotype 3, in whom liver cirrhosis was ruled out by abdominal ultrasound, were included in the study, by non-probability convenience sampling. A combination of DCV (60mg) and SOV(400mg) orally once daily for 12 weeks was given to all and were followed up in the OPD for 12 weeks after treatment. After 12 weeks of completion of treatment, HCV PCR was checked to evaluate the SVR after 12 weeks (SVR-12).

Results

Out of 75 patients, male patients were 56% while female patients were 44%. The mean age was 48.65 ± 13.72 years. Diabetes mellitus was present in 62.7% of the patients. SVR-12 was achieved in 85.3% which showed insignificant association with gender (p-value 0.916), diabetes mellitus (p-value 0.455) and age (p-value 0.076).

Conclusion

Achieving an SVR-12 rate of 85.3% depicts that the combination of DCV and SOV is extremely efficient in treating the HCV genotype 3, Its efficacy is consistent across patients, regardless of age, gender, or diabetes mellitus.

Zitieren

APA

Virk, S. T., Yousaf, S., Virk, K. A., Umer, Z., Zafar, A., & Ahmad, M. (2025). Efficacy Of The Combination Of Daclatasvir And Sofosbuvir For The Management Of Hcv Genotype 3 Patients. HITEC Medical and Dental Journal. https://doi.org/10.69884/hmdj.4.2.3963

Vancouver

Virk ST, Yousaf S, Virk KA, Umer Z, Zafar A, Ahmad M. Efficacy Of The Combination Of Daclatasvir And Sofosbuvir For The Management Of Hcv Genotype 3 Patients. HITEC Medical and Dental Journal. 2025. doi:10.69884/hmdj.4.2.3963

BibTeX
@article{Virk2025,
  author = {Virk, Sana Tahir and Yousaf, Sadaf and Virk, Kazim Abbas and Umer, Zaid and Zafar, Abeer and Ahmad, Mahwish},
  title = {Efficacy Of The Combination Of Daclatasvir And Sofosbuvir For The Management Of Hcv Genotype 3 Patients},
  journal = {HITEC Medical and Dental Journal},
  year = {2025},
  doi = {10.69884/hmdj.4.2.3963}
}
Kostenlos starten →